SAN FRANCISCO Biotechnology giant Amgen Inc expects up to a quarter of its growth to come from Asia over the next decade, Chief Executive Officer Robert Bradway told Reuters.
SAN DIEGO/CHICAGO Biogen Inc on Thursday laid out more data on its experimental Alzheimer's drug that raised no major safety alarms but also offered little compelling evidence the drug, once declared a failure, actually works.
SAN DIEGO/CHICAGO, Dec 5 Biogen Inc on
Thursday presented new data on its experimental Alzheimer's drug
aducanumab that eased concerns raised by some experts but still
left many questions unanswered as the company made its case
about why it plans to seek U.S. approval after declaring the
drug a failure in March.
SAN DIEGO, Dec 5 Biogen Inc, looking to
win over skeptics and health regulators, later on Thursday will
present highly anticipated data on its experimental Alzheimer's
drug aducanumab, which the U.S. biotech company had declared a
failure earlier this year.
U.S. President Donald Trump plans to nominate Dr. Stephen Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the Food and Drug Administration, the White House said on Friday.
LOS ANGELES Amgen Inc said on Thursday it will take a 20.5% stake in BeiGene Ltd in a deal to expand the California-based biotechnology company's presence in China, the world's second largest pharmaceutical market.
LOS ANGELES, Oct 31 Amgen Inc said on
Thursday it will acquire a 20.5% stake in BeiGene Ltd
in a deal that will enable the California-based biotechnology
company to expand its presence in China, the world's second
largest pharmaceutical market.
Amgen Inc on Tuesday said competition for its older drugs sent third-quarter revenue down 3%, but biosimilar sales were strong and the quarterly results were ahead of Wall Street estimates.
Oct 29 Amgen Inc on Tuesday said
competition for older off-patent drugs sent third-quarter
revenue down 3%, but share repurchases and biosimilar sales
helped it achieve higher-than-expected profit, and the company
raised its full-year outlook.
An experimental drug from Mirati Therapeutics Inc that targets a specific genetic mutation significantly reduced tumor size in 40% of patients with advanced lung and colorectal cancer so far evaluated in a small, early-stage trial, researchers said on Monday.